On Wednesday, Oppenheimer made a significant adjustment to Zentalis Pharmaceuticals' (NASDAQ:ZNTL) price target, reducing it from $20.00 to $10.00, while keeping a Perform rating on the company's shares. The revision follows the release of new data from Zentalis regarding their drug azenosertib, marking the first data readout in over two years.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.